Madrigal Pharmaceuticals (MDGL) Current Assets (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Current Assets for 17 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Assets rose 19.52% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $1.2 billion (up 19.52% YoY), while the FY2025 annual figure was $1.2 billion, up 20.61% from the prior year.
• Current Assets climbed to $1.2 billion in Q2 2026 per MDGL's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.3 billion in Q3 2025 and bottomed at $157.1 million in Q3 2022.
• Historically, Current Assets has averaged $760.4 million across 5 years, with a median of $995.7 million in 2025.
• Annual changes were most pronounced in 2022 — Current Assets slumped 48.14% — and 2024, when it soared 351.72%.
• Madrigal Pharmaceuticals' Current Assets stood at $361.4 million in 2022, then soared by 76.35% to $637.3 million in 2023, then surged by 62.08% to $1.0 billion in 2024, then increased by 20.61% to $1.2 billion in 2025, then fell by 3.74% to $1.2 billion in 2026.
• Business Quant data shows MDGL's Current Assets at $1.2 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.2 billion in Q4 2025.